Difference between revisions of "Lenalidomide (Revlimid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>")
(updated content)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to [[Thalidomide (Thalomid)]]; mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells.  It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes.  It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.<ref name="insert">[http://www.revlimid.com/pdf/REVLIMID_PI.pdf Lenalidomide (Revlimid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/lenalidomide.pdf Lenalidomide (Revlimid) package insert (locally hosted backup)]</ref><ref>[http://revlimid.com/ Revlimid manufacturer's site]</ref><ref name="revassist">[http://revlimid.com/hcp/RevAssist.aspx RevAssist program]</ref>
+
Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to [[Thalidomide (Thalomid)]]; mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells.  It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes.  It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021880s034lbl.pdf Lenalidomide (Revlimid) package insert]</ref><ref>[[Media:Lenalidomide.pdf|Lenalidomide (Revlimid) package insert (locally hosted backup)]]</ref><ref>[http://revlimid.com/ Revlimid manufacturer's site]</ref><ref name="revassist">[http://revlimid.com/hcp/RevAssist.aspx RevAssist program]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
Line 6: Line 6:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 +
==Diseases for which it is used==
 +
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]
 +
*[[Follicular lymphoma]]
 +
*[[Light-chain (AL) amyloidosis]]
 +
*[[Mantle cell lymphoma]]
 +
*[[Multiple myeloma]]
 +
*[[Myelodysplastic syndrome]]
  
 
==Patient drug information==
 
==Patient drug information==
 +
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021880s034lbl.pdf#page=28 Lenalidomide (Revlimid) package insert PDF pages 28-33]<ref name="insert"></ref>
 
*[http://revlimid.com/docs/Revlimid_Med_Guide.pdf Lenalidomide (Revlimid) patient medication guide]<ref>[http://revlimid.com/docs/Revlimid_Med_Guide.pdf Lenalidomide (Revlimid) patient medication guide]</ref>
 
*[http://revlimid.com/docs/Revlimid_Med_Guide.pdf Lenalidomide (Revlimid) patient medication guide]<ref>[http://revlimid.com/docs/Revlimid_Med_Guide.pdf Lenalidomide (Revlimid) patient medication guide]</ref>
−
*[http://chemocare.com/bio/lenalidomide.asp Lenalidomide (Revlimid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/lenalidomide.asp Lenalidomide (Revlimid) patient drug information (Chemocare)]</ref>
+
*[http://chemocare.com/chemotherapy/drug-info/Lenalidomide.aspx Lenalidomide (Revlimid) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Lenalidomide.aspx Lenalidomide (Revlimid) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
*12/28/2005: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108546.htm FDA approved] for patients with "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities."<ref name="insert"></ref>
 +
*6/29/2006: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm FDA approved] for treatment of patients with "multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy.]<ref name="insert"></ref>
 +
*6/5/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm FDA approved] for patients with "mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."<ref name="insert"></ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drug index]]
 +
[[Category:Chemotherapy]]
 +
[[Category:Immunomodulatory drugs (IMiDs)]]
 +
[[Category:Multiple myeloma medications]]

Revision as of 18:31, 5 June 2013

General information

Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.[1][2][3][4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 12/28/2005: FDA approved for patients with "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities."[1]
  • 6/29/2006: FDA approved for treatment of patients with "multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy.][1]
  • 6/5/2013: FDA approved for patients with "mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."[1]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Lenalidomide (Revlimid) package insert
  2. ↑ Lenalidomide (Revlimid) package insert (locally hosted backup)
  3. ↑ Revlimid manufacturer's site
  4. ↑ 4.0 4.1 RevAssist program
  5. ↑ Lenalidomide (Revlimid) patient medication guide
  6. ↑ Lenalidomide (Revlimid) patient drug information (Chemocare)
  7. ↑ Lenalidomide (Revlimid) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Lenalidomide_(Revlimid)&oldid=2967"